bluebird bio Inc. (BLUE)

135.75
3.10 2.34
NASDAQ : Health Technology
Prev Close 132.65
Open 133.27
Day Low/High 132.03 / 137.55
52 Wk Low/High 87.49 / 183.00
Volume 463.06K
Avg Volume 537.00K
Exchange NASDAQ
Shares Outstanding 55.12M
Market Cap 7.39B
EPS -10.70
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Trump's Trade War Against U.S. Allies Is a Direct Hit to Key Industries

Trump's Trade War Against U.S. Allies Is a Direct Hit to Key Industries

Diplomacy must precede presidential threats.

3 Potential Biotech Buyout Targets in the Second Quarter

3 Potential Biotech Buyout Targets in the Second Quarter

Novartis' deal for AveXis has ignited a rally in other gene-therapy concerns.

Possible Biotech Takeout Plays

Possible Biotech Takeout Plays

A look at possible second-quarter M&A activity in the biotech sector.

Which Hot Biotech Name Will Be Acquired Next?

Which Hot Biotech Name Will Be Acquired Next?

Your burning biotech questions answered in our latest mailbag.

Bret Jensen's Biotech Mailbag

Bret Jensen's Biotech Mailbag

We'll answer two of the common questions we have received so far in March.

2 Biotech Acquisition Candidates That Could Be Next in M&A Crosshairs

2 Biotech Acquisition Candidates That Could Be Next in M&A Crosshairs

Outside of oncology, the rare disease area is a good target for M&A in 2018.

Circle These Biotech Acquisition Candidates

Circle These Biotech Acquisition Candidates

Outside of oncology, the rare disease area is a good target for M&A in 2018.

How Trading Notes Can Increase Your Profits

How Trading Notes Can Increase Your Profits

Inertia is your biggest enemy in this market.

Video: Jim Cramer on Bitcoin, Bluebird Bio and This Weeks Fed Meeting

Video: Jim Cramer on Bitcoin, Bluebird Bio and This Weeks Fed Meeting

TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer weighs in on Monday's trending topics including bitcoin futures, Bluebird Bio and what to expect from this week's Federal Reserve meeting.

Blueprint Medicines and Bluebird Bio Soar on ASH Announcements -- Biotech Movers

Blueprint Medicines and Bluebird Bio Soar on ASH Announcements -- Biotech Movers

Blueprint unveiled new data from its ongoing Phase 1 study of avapritinib in advanced systemic mastocytosis at the 59th American Society of Hematology Annual Meeting.

Price Momentum Still the Key, as Tax Reform and the Fed Are Ignored

Price Momentum Still the Key, as Tax Reform and the Fed Are Ignored

There are some signs of selling into the strength especially in technology names.

Bluebird Bio New Overweight at Barclays

Cramer: Fantasy Shmantasy -- Let's Get Real With These Stock Picks

Cramer: Fantasy Shmantasy -- Let's Get Real With These Stock Picks

This team is playoff-ready and built for the ages.

Entry Points Are Tough, and Post-Labor Day Action Is Historically Poor

Entry Points Are Tough, and Post-Labor Day Action Is Historically Poor

I've cut a few positions and haven't made any notable buys today.

Cramer: There Should Be More Takeovers Where These Came From

Cramer: There Should Be More Takeovers Where These Came From

Buying's good for the acquirers, which should give other companies ideas.

Kite Takeover by Gilead Lifts Biotech Stocks

Kite Takeover by Gilead Lifts Biotech Stocks

The key to dealing with this environment is to keep an open mind.

Time to Take Profits in Bluebird Bio

Time to Take Profits in Bluebird Bio

This biotech has done well so far this year, but now it's time to lock in some gains.

BMO Raises Bluebird Bio to Outperform

Bluebird Bio Looks Set to Soar Upward

Bluebird Bio Looks Set to Soar Upward

Meal worms not needed to give it strength.

Oil Prices Keep Rising on OPEC Deal; Bluebird, Celgene T-Cell Therapy Sees Success

Oil Prices Keep Rising on OPEC Deal; Bluebird, Celgene T-Cell Therapy Sees Success

Oil prices continued their upward climb Thursday, buoyed by Wednesday's landmark OPEC agreement.

Why Celgene Is a Core Biotech Holding

Why Celgene Is a Core Biotech Holding

Celgene's days of stellar growth will continue to stretch far into the future.

Trader's Daily Notebook: You Might Consider Selling Facebook

Trader's Daily Notebook: You Might Consider Selling Facebook

Do that if you like top ticking crowd favorites, but set a protective stop.

Four Stellar Stocks to Beat the Biotech Slump

Four Stellar Stocks to Beat the Biotech Slump

Biotech stocks are struggling this year, but investors should not throw in the towel on Amgen, Gilead, bluebird and Bellicum

4 Stocks to Play In Today's Market

4 Stocks to Play In Today's Market

Always trade the environment that you find yourself in.

2 'Rules of the Road' for Biotech Investing

2 'Rules of the Road' for Biotech Investing

Follow these maxims and you should do well in this volatile sector.

Midday Report: Keurig Deal Boosts Peers; Energy Stocks Slump

Midday Report: Keurig Deal Boosts Peers; Energy Stocks Slump

Energy stocks were hammered and pulled benchmark indexes lower by midday Monday.

Bluebird Bio downgraded at BofA/Merrill